These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 23060265)

  • 21. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
    Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
    Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
    Dean E; Lorigan P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [BRAF mutation detection in metastatic melanoma].
    Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
    Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
    [No Abstract]   [Full Text] [Related]  

  • 27. [From a mutation to a drug].
    Wnuk J; Wilanowski T
    Postepy Biochem; 2023 Sep; 69(3):178-187. PubMed ID: 38019740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.
    Kemper K; Krijgsman O; Cornelissen-Steijger P; Shahrabi A; Weeber F; Song JY; Kuilman T; Vis DJ; Wessels LF; Voest EE; Schumacher TN; Blank CU; Adams DJ; Haanen JB; Peeper DS
    EMBO Mol Med; 2015 Sep; 7(9):1104-18. PubMed ID: 26105199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
    Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
    J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
    [No Abstract]   [Full Text] [Related]  

  • 30. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
    Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabrafenib therapy for advanced melanoma.
    Trinh VA; Davis JE; Anderson JE; Kim KB
    Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
    Saint-Jean M; Quéreux G; Nguyen JM; Peuvrel L; Brocard A; Vallée A; Knol AC; Khammari A; Denis MG; Dréno B
    J Invest Dermatol; 2014 May; 134(5):1468-1470. PubMed ID: 24025553
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA approves vemurafenib for treatment of metastatic melanoma.
    Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
    [No Abstract]   [Full Text] [Related]  

  • 35. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
    Wagle N; Emery C; Berger MF; Davis MJ; Sawyer A; Pochanard P; Kehoe SM; Johannessen CM; Macconaill LE; Hahn WC; Meyerson M; Garraway LA
    J Clin Oncol; 2011 Aug; 29(22):3085-96. PubMed ID: 21383288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Community experience of vemurafenib for BRAF(V600) melanoma.
    Hersey P
    Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
    [No Abstract]   [Full Text] [Related]  

  • 39. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.